Correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic Fibrosis in MASlD With type2 Diabetes Mellitus

ConditionHepatic Fibrosis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age30-65

SponsorSohag University

About this trial

Metabolic dysfunction asociated steatotic liver disease prevalence is 25%world wide diabetic patients have a risk for MASLD then have hepatic fibrosis so we study correlation Between Serum Adiponectin And Resistin Levels And Degree of Hepatic fibrosis In Metabolic dysfunction asociated steatotic liver disease in patients with type2 Diabetes Mellitus

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients of both sex who have type2 Diabetes Mellitus for less than five years

Disqualifiers

None

Trial population

MASLD patients with hepatic fibrosis groupA,MASLD patients without hepatic fibrosis

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

serum Adiponectine and Resistin
Diagnostic test
corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis
fibroscan
Diagnostic test
hepatic fibrosis detection in type 2 diabetes mellutis

Treatment groups

80 Participants

are divided into 2 treatment groups

Group A: MASLD patients with hepatic fibrosis2 interventions

Group B: MASLD without hepatic fibrosis2 interventions

Trial outcomes

Primary outcomes

degree of hepatic fibrosis in MASLD with type 2 diabetes mellitus

adiponectineand resistine level with degree of hepatic fibrosis in MASLD pt. with type 2 DM

Time frame

1 year

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: